Jim Simons Poseida Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

$63.6 Billion
Q1 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Poseida Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 557,400 shares of PSTX stock, worth $1.63 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

557,400

Previous 530,100 5.15%

Holding current value

$1.63 Million

Previous $1.78 Million 0.17%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$2.76 - $4.13 $75,348 - $112,749	27,300 Added 5.15%	557,400 $1.78 Million
Q4 2023 Feb 13, 2024	SELL	$1.83 - $3.51 $462,936 - $887,928	-252,971 Reduced 32.3%	530,100 $1.78 Million
Q3 2023 Nov 14, 2023	BUY	$1.62 - $2.79 $393,736 - $678,101	243,047 Added 45.01%	783,071 $1.86 Million
Q2 2023 Aug 11, 2023	SELL	$1.66 - $3.4 $104,872 - $214,798	-63,176 Reduced 10.47%	540,024 $950,000
Q1 2023 May 12, 2023	BUY	$3.08 - $8.73 $1.25 Million - $3.55 Million	406,900 Added 207.28%	603,200 $1.86 Million

Q4 2022 Feb 13, 2023	SELL	$4.04 - $6.38 $593,880 - $937,860	-147,000 Reduced 42.82%	196,300 $1.04 Million
Q3 2022 Nov 14, 2022	SELL	$2.43 - $4.51 $89,424 - $165,968	-36,800 Reduced 9.68%	343,300 $1.21 Million
Q2 2022 Aug 12, 2022	BUY	$1.87 - $5.0 $361,097 - $965,500	193,100 Added 103.26%	380,100 $981,000
Q1 2022 May 13, 2022	BUY	$3.22 - $7.04 $493,948 - $1.08 Million	153,400 Added 456.55%	187,000 $838,000
Q4 2021 Feb 11, 2022	BUY	$6.23 - $7.6 $128,961 - $157,320	20,700 Added 160.47%	33,600 $229,000
Q3 2021 Nov 12, 2021	BUY	$7.09 - $10.71 $91,461 - $138,159	12,900 New	12,900 $94,000

Others Institutions Holding PSTX

# of Institutions

Shares Held

38.1M

Call Options Held

255K

Put Options Held

62K

View Full List

About Poseida Therapeutics, Inc.

Ticker PSTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,775,600
Market Cap $250M
Description
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...

More about PSTX

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account